Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study.
Houchen LyuSizheng Steven ZhaoLicheng ZhangJie WeiXiaoxiao LiHui LiYi LiuPengbin YinVibeke NorvangKazuki YoshidaSara K TedeschiChao ZengGuang-Hua LeiPei-Fu TangDaniel H SolomonPublished in: BMJ (Clinical research ed.) (2023)
In this population based study, denosumab use was associated with a lower risk of incident type 2 diabetes compared with oral bisphosphonate use in adults with osteoporosis. This study provides evidence at a population level that denosumab may have added benefits for glucose metabolism compared with oral bisphosphonates.